Drug Potency Prediction of SARS-CoV-2 Main Protease Inhibitors Based on a Graph Generative Model

Author:

Fadlallah Sarah1ORCID,Julià Carme1ORCID,García-Vallvé Santiago2ORCID,Pujadas Gerard2ORCID,Serratosa Francesc1ORCID

Affiliation:

1. Research Group ASCLEPIUS: Smart Technology for Smart Healthcare, Departament d’Enginyeria Informàtica i Matemàtiques, Universitat Rovira i Virgili, 43007 Tarragona, Spain

2. Research Group in Cheminformatics and Nutrition, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, 43007 Tarragona, Spain

Abstract

The prediction of a ligand potency to inhibit SARS-CoV-2 main protease (M-pro) would be a highly helpful addition to a virtual screening process. The most potent compounds might then be the focus of further efforts to experimentally validate their potency and improve them. A computational method to predict drug potency, which is based on three main steps, is defined: (1) defining the drug and protein in only one 3D structure; (2) applying graph autoencoder techniques with the aim of generating a latent vector; and (3) using a classical fitting model to the latent vector to predict the potency of the drug. Experiments in a database of 160 drug-M-pro pairs, from which the pIC50 is known, show the ability of our method to predict their drug potency with high accuracy. Moreover, the time spent to compute the pIC50 of the whole database is only some seconds, using a current personal computer. Thus, it can be concluded that a computational tool that predicts, with high reliability, the pIC50 in a cheap and fast way is achieved. This tool, which can be used to prioritize which virtual screening hits, will be further examined in vitro.

Funder

Universitat Rovira i Virgili through the Martí Franquès program in addition to AGAUR research groups

Publisher

MDPI AG

Subject

Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis

Reference29 articles.

1. Achdout, H., Aimon, A., Bar-David, E., and Morris, G.M. (2020). COVID Moonshot: Open Science Discovery of SARS-CoV-2 Main Protease Inhibitors by Combining Crowdsourcing, High-Throughput Experiments, Computational Simulations, and Machine Learning. bioRxiv.

2. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19;Owen;Science,2021

3. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19;Eastman;ACS Cent. Sci.,2020

4. (2023, March 20). U.S. Food and Drug Administration to Treat COVID-19, Available online: https://fda.gov/drugs/emergency-preparedness-drugs/coronavirus-covid-19-drugs.

5. Gimeno, A., Mestres-Truyol, J., Ojeda-Montes, M.J., Macip, G., Saldivar-Espinoza, B., Cereto-Massagué, A., Pujadas, G., and Garcia-Vallvé, S. (2020). Prediction of novel inhibitors of the main protease (M-pro) of SARS-CoV-2 through consensus docking and drug reposition. Int. J. Mol. Sci., 21.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3